AbstractPositron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-SD-glucose (18F-FDG PET) has been recognized as a noninvasive imaging modality used in oncology for the initial diagnosis, staging, restaging, and evaluation of response to treatment in numerous malignancies. The use of 18F-FDG
No takes yet. Share an insight, caveat, or question.
Rosioreanu et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: